IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Karin Butz et al.

Title: LIVIN-SPECIFIC siRNAs FOR

THE TREATMENT OF THERAPY-RESISTANT

TUMORS

Appl. No.: 10/553,355

International

October 14, 2005

Filing Date: 371(c) Date:

Examiner: Unassigned

Art Unit: Unassigned

6994

Confirmation

Number:

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be

appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first official action on the merits.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

The documents listed on the PTO/SB/08 were cited in the specification, and the European Search Report for parent international application no. PCT/EP2004/003974, a copy of the European Search Report was filed with the U.S. Patent Office on October 14, 2005, along with the above National Phase Application.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted,

Date

FOLEY & LARDNER LLP

Customer Number: 22428

Telephone: Facsimile:

(202) 672-5538

(202) 672-5399

Michele M. Simkin Attorney for Applicant

By Michael M S/11.

Registration No. 34,717

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.

	Substitute for fe	orm 1449B/	PTO	Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/553,355	
	STATEMENT I	BY APPLI	CANT	Filing Date	October 14, 2005	
Date Submitted: July 5, 2006				First Named Inventor	Karin Butz	
	Date Submitte	ea. July 5,	2000	Group Art Unit	Unassigned	
(use as many sheets as necessary)				Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	085449-0180	

U.S. PATENT DOCUMENTS							
0.11-	U.S. Patent Document		N A STATE OF THE S	Date of Publication of	Pages, Columns, Lines, Where Relevant		
No.1	Number	Kind Code ² (if known)	Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		
	Cite No. ¹	Cite	Cite Kind No.1 Number Code ² (if	Cite No.1 Number Kind Name of Patentee or Applicant of Code ² (if Cited Document	Cite No.1 Number Code2 (if Name of Patentee or Applicant of Cited Document MM-DD-YYYY		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Тв	
	A1	WO 00/77201	A1	Gomes et al.	12/21/2000			
	A2	WO 03/018763	A2	Testa et al.	03/06/2003			
	A3	WO 03/106974	A2	Deveraux et al.	12/24/2003			

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in Caenorhabditis Elegans," Letters to Nature, Feb. 1998, Vol. 391, pgs. 806-811. Elbashir et al., "Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells," Letters to Nature, 2001, Vol. 411, pgs. 494-498. Williams et al., "Identification and Validation of Genes Involved in the Pathogenesis of Colorectal Cancer Using cDNA Microarrays and RNA Interference," Clinical Cancer Research, Mar. 2003, Vol. 9, pgs. 931-946. Brummelkamp et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells,"	т*
Letters to Nature, Feb. 1998, Vol. 391, pgs. 806-811. Elbashir et al., "Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells," Letters to Nature, 2001, Vol. 411, pgs. 494-498. Williams et al., "Identification and Validation of Genes Involved in the Pathogenesis of Colorectal Cancer Using cDNA Microarrays and RNA Interference," Clinical Cancer Research, Mar. 2003, Vol. 9, pgs. 931-946.	
Letters to Nature, 2001, Vol. 411, pgs. 494-498. Williams et al., "Identification and Validation of Genes Involved in the Pathogenesis of Colorectal Cancer Using cDNA Microarrays and RNA Interference," Clinical Cancer Research, Mar. 2003, Vol. 9, pgs. 931-946.	
Using cDNA Microarrays and RNA Interference," Clinical Cancer Research, Mar. 2003, Vol. 9, pgs. 931-946.	
Brummelkamp et al. "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells."	
SCIENCE, Apr. 2002, Vol. 296, pgs. 550-553.	
Sui et al., "A DNA Vector-Based RNAi Technology to Suppress Gene Expression in Mammalian Cells," Proc. Natl. Acad. Sci., 2002, Vol. 99, pgs. 5515-5520.	
Lee et al., "Expression of Small Interfering RNAs Targeted Against HIV-1 rev Transcripts in Human Cells," Nature Biotechnology, May 2002, Vol. 19, pgs. 500-505.	
Morris et al., "Translocating Peptides and Proteins and their use for Gene Delivery," Curr. Opin. Biotech., 2000, Vol. 11(5), pgs. 461-466.	
	Proc. Natl. Acad. Sci., 2002, Vol. 99, pgs. 5515-5520. Lee et al., "Expression of Small Interfering RNAs Targeted Against HIV-1 rev Transcripts in Human Cells," Nature Biotechnology, May 2002, Vol. 19, pgs. 500-505. Morris et al., "Translocating Peptides and Proteins and their use for Gene Delivery," Curr. Opin. Biotech.,

Examiner	Date Considered	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.